XML 44 R32.htm IDEA: XBRL DOCUMENT v3.25.3
Other Financial Statement Information - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
May 31, 2025
Feb. 28, 2025
Sep. 30, 2025
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Concentration Risk [Line Items]                
Debt securities, available-for-sale, realized gain (loss)       $ 0 $ 0 $ 0 $ 0  
Gross Carrying Amount     $ 77,416 77,416   77,416   $ 25,777
Transaction price allocated to remaining performance obligations     33,000 33,000   33,000    
Deferred revenue     22,139 22,139   22,139   20,658
Contract liability     33,000 33,000   33,000   33,200
Gain on settlement       0 0 49,900 0  
Revenue       149,002 151,654 476,793 445,764  
Recognized foreign currency transaction income (loss)       (600) 1,300 3,100 300  
Change in fair value           1,135 0  
Scale BioScience Inc. Acquisition                
Concentration Risk [Line Items]                
Change in fair value     1,100 1,100   1,135    
Developed technology                
Concentration Risk [Line Items]                
Gross Carrying Amount     52,639 52,639   52,639   1,000
Developed technology | Scale BioScience Inc. Acquisition                
Concentration Risk [Line Items]                
Gross Carrying Amount     51,600 51,600   51,600    
Assembled workforce                
Concentration Risk [Line Items]                
Gross Carrying Amount     1,328 1,328   1,328   $ 1,328
Impairment of long lived assets       700        
Assembled workforce | Scale BioScience Inc. Acquisition                
Concentration Risk [Line Items]                
Gross Carrying Amount     $ 700 $ 700   $ 700    
Vizgen, Inc.                
Concentration Risk [Line Items]                
Amount of litigation settlement and intellectual property license granted   $ 26,000            
Gain on settlement   9,200            
Bruker Corporation                
Concentration Risk [Line Items]                
Amount of litigation settlement and intellectual property license granted $ 68,000              
Gain on settlement 40,700              
Revenue $ 27,300              
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01                
Concentration Risk [Line Items]                
Expected period of revenue recognition     12 months 12 months   12 months    
Products and Services, Excluding Grant Revenue                
Concentration Risk [Line Items]                
Deferred revenue     $ 22,100 $ 22,100   $ 22,100    
License and royalty revenue                
Concentration Risk [Line Items]                
Revenue       $ 983 $ 95 $ 45,794 $ 210  
License and royalty revenue | Vizgen, Inc.                
Concentration Risk [Line Items]                
Revenue   $ 16,800